CG Oncology, Inc. unveils peer-reviewed clinical findings for advanced bladder cancer therapy

Traders Union
All News
Business & Wealth
CG Oncology releases Phase 3 results

Top Stories

Editors' Picks

Stocks

Crypto

Economics

Currencies

Commodities

Business & Wealth

Market Voices

Ivan Andriyenko

10 hours ago

CG Oncology, Inc. unveils peer-reviewed clinical findings for advanced bladder cancer therapy — CG Oncology releases Phase 3 results

CG Oncology, Inc. has published results from its Phase 3 BOND-003 Cohort C clinical trial in The Lancet Oncology.

The peer-reviewed study focuses on evaluating complete response rates, duration of response, and safety profile for patients, underscoring progress in the development of therapies for bladder cancer. The publication is expected to provide new insights for clinicians and researchers into innovative treatment approaches for this medical condition.

Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Earlier this year, CG Oncology brought on David Fela as vice president to boost analytical development and quality control during ongoing clinical progress. The appointment was aimed at strengthening internal standards as the company advanced its research pipeline. The latest Phase 3 results follow this recent leadership expansion.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Did you like the article?

Editor's Picks for You

Allbridge co-founder: Many people do not even realize they are using crypto bridges

By Eugene Komchuk
1 hour ago

Allbridge co-founder: Many people do not even realize they are using crypto bridges

Editors' Picks

Bitcoin mining is getting greener, but the debate isn't over

By Anastasiia Chabaniuk
21 hours ago

Bitcoin mining is getting greener, but the debate isn't over

Editors' Picks

Asia's largest IPO: How CXMT became China's most valuable company

By Mikhail Vnuchkov
Yesterday

Asia's largest IPO: How CXMT became China's most valuable company

Editors' Picks

All Editors' Top Picks

Latest CG Oncology News

CG Oncology appoints David Fela as vice president to strengthen quality control focus

By Oleg Tkachenko
23.07.2026

CG Oncology appoints David Fela as vice president to strengthen quality control focus

Companies

CG Oncology CEO Arthur Kuan to present at Jefferies and Goldman Sachs healthcare events

By Yaroslav Dmytrenko
29.05.2026

CG Oncology CEO Arthur Kuan to present at Jefferies and Goldman Sachs healthcare events

Companies

CG Oncology, Inc. engages with urology leaders at AUA26 to advance patient care connections

By Yaroslav Dmytrenko
18.05.2026

CG Oncology, Inc. engages with urology leaders at AUA26 to advance patient care connections

Companies

All CG Oncology News

Eugene Komchuk
1 hour ago

Allbridge co-founder: Many people do not even realize they are using crypto bridges

Anastasiia Chabaniuk
21 hours ago

Bitcoin mining is getting greener, but the debate isn't over

Mikhail Vnuchkov
Yesterday

Asia's largest IPO: How CXMT became China's most valuable company

Pavlo Kot
26.07.2026

Global fintech in 2026: Three trends that matter

Pavlo Kot
25.07.2026

From Jesus Christ to aliens: Polymarket's most absurd prediction markets

Yaroslav Dmytrenko
22 min ago

Non-Bitcoin chains now cater to USD-based crypto payments, Fernando Nikolic notes

Jose Antonio Gastelum
37 min ago

Tony Katz: Europe cutting off Binance may trigger global exchange decline

Igor Krasulya
52 min ago

Nearly 15,000 gold futures contracts trade in launch weekend, Peter Spina notes

Daria Chernytska
1 hour ago

Richard Teng: Stablecoins and tokenized stocks set to lead in 2026

Yaroslav Dmytrenko
1 hour ago

Scott Melker: TD Cowen cuts Nakamoto NAKA price target to $17 after Bitcoin outlook reset

Weekly Top Bonuses

Capitalcore

up to $2,500
deposit bonus for all clients

Your capital is at risk.

Top News

Eugene Komchuk
13 min ago

Musk begins U.S. rollout of X Money banking service

Musk begins U.S. rollout of X Money banking service

Olga Shendetskaya
38 min ago

Oil retreats as markets trim Middle East risk premium

Oil retreats as markets trim Middle East risk premium

Ivan Andriyenko
1 hour ago

SK Hynix shares tumble as global chip selloff deepens

SK Hynix shares tumble as global chip selloff deepens

Eugene Komchuk
1 hour ago

Allbridge co-founder: Many people do not even realize they are using crypto bridges

Allbridge co-founder: Many people do not even realize they are using crypto bridges

Andrey Mastykin
2 hours ago

Trump signals renewed push for Iran agreement amid regional calm

Trump signals renewed push for Iran agreement amid regional calm

Top 5 companies for you

United States

Live News

Mykhailo Ihnatenko
Now

Unilever shares jump over 6% after strong H1 results

Mykhailo Ihnatenko
Now

Rolls-Royce shares test key resistance ahead of earnings

Mykhailo Ihnatenko
Now

GRAM price risks drop to $1.36 as crypto selloff deepens

Mykhailo Ihnatenko
Now

Ethereum rally loses momentum as global risks intensify

Anton Kharitonov
Now

Alphabet remains under pressure as AI investment concerns overshadow strong cloud growth

© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186

Risk disclosure:

Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.
Disclaimer:

Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.
Disclosure of advertisers and revenues:

All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.